<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096768</url>
  </required_header>
  <id_info>
    <org_study_id>FA2.2016.R2.21/Jun/2019</org_study_id>
    <nct_id>NCT04096768</nct_id>
  </id_info>
  <brief_title>The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation</brief_title>
  <official_title>Combining Dexmedetomidine and Ketamine in Intensive Care Sedation: Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lebanese American University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lebanese American University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the use of dexmedetomidine + ketamine with dexmedetomidine
      + placebo for sedation in ICU patients in terms of safety and efficacy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring blood pressure to assess hypotension when using a combination of the two drugs for sedation versus Dexmedetomidine and placebo only</measure>
    <time_frame>Within 24 hours of drugs administration</time_frame>
    <description>Measuring blood pressure to assess hypotension when using a combination of the two drugs for sedation versus Dexmedetomidine and placebo only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring the doses of dexmedetomidine and ketamine when combined and the doses of dexmedetomidine when used alone to achieve desired level of sedation</measure>
    <time_frame>Within 24 hours of drugs administration</time_frame>
    <description>Measuring the doses of dexmedetomidine and ketamine when combined and the dose of dexmedetomidine when used alone to achieve desired level of sedation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>ICU Patients</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine + Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients</description>
    <arm_group_label>Dexmedetomidine + Ketamine</arm_group_label>
    <arm_group_label>Dexmedetomidine + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients</description>
    <arm_group_label>Dexmedetomidine + Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-80 years old

          -  Admitted to Intensive care unit at LAUMCRH

          -  Need for sedation for at least 24 hours

          -  Informed Consent Form signed by patient or surrogate

        Exclusion Criteria:

          -  Pregnant patients

          -  At risk of increased intracranial pressure

          -  Aortic dissection

          -  Acute coronary syndrome

          -  Hypertension (SBP &gt; 180 mmHg)

          -  Chronic alcoholism

          -  Acute alcohol intoxication

          -  Alcohol withdrawal

          -  Refractory status epilepticus

          -  History of psychiatric disorder

          -  Known allergy or contraindication to use of dexmedetomidine or ketamine

          -  Baseline hypotension (MAP&lt;65 mmHg)

          -  Baseline bradycardia (HR&lt;48 bpm)

          -  Patients receiving neuromuscular blocking agents

          -  Patients requiring deep sedation as determined by the ICU attending
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fayez Abillama, MD</last_name>
    <phone>01200800</phone>
    <phone_ext>6420</phone_ext>
    <email>fayez.abillama@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lebanese American University Medical Center- Rizk Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>00000</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fayez Abillama, MD</last_name>
      <phone>01200800</phone>
      <phone_ext>6420</phone_ext>
      <email>fayez.abillama@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yara Kuyumdjian, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lebanese American University Medical Center</investigator_affiliation>
    <investigator_full_name>Fayez Abillama, MD</investigator_full_name>
    <investigator_title>Intensive Care Medicine Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

